Phase 2 × Completed × Waldenstrom Macroglobulinemia × Clear all Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia
Phase 2 Completed
25 enrolled
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Phase 2 Completed
96 enrolled
A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)
Phase 2 Completed
16 enrolled 14 charts
PembroWM
Phase 2 Completed
17 enrolled 7 charts
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
Phase 2 Completed
44 enrolled 13 charts
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 2 Completed
65 enrolled 21 charts
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Phase 2 Completed
35 enrolled
RemodelWM3
Phase 2 Completed
50 enrolled
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Phase 2 Completed
21 enrolled 14 charts
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
77 enrolled
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Phase 2 Completed
50 enrolled 11 charts
Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing
Phase 2 Completed
31 enrolled 12 charts
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Phase 2 Completed
13 enrolled 11 charts
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 2 Completed
41 enrolled 8 charts
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
Phase 2 Completed
33 enrolled 15 charts
A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531
Phase 2 Completed
7 enrolled 10 charts
R2W
Phase 2 Completed
60 enrolled
Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
59 enrolled
LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia
Phase 2 Completed
39 enrolled 13 charts
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2 Completed
6 enrolled 16 charts
FIL_BRB
Phase 2 Completed
38 enrolled
Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)
Phase 2 Completed
63 enrolled 10 charts
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
Phase 2 Completed
56 enrolled 12 charts
Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia
Phase 2 Completed
26 enrolled 14 charts
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Phase 2 Completed
14 enrolled
Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia
Phase 2 Completed
8 enrolled
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia
Phase 2 Completed
199 enrolled 14 charts
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase 2 Completed
36 enrolled 13 charts
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Phase 2 Completed
63 enrolled 12 charts
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
47 enrolled 18 charts
VCR
Phase 2 Completed
24 enrolled 11 charts
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase 2 Completed
77 enrolled 10 charts
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
210 enrolled 15 charts
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 2 Completed
277 enrolled 11 charts
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed
42 enrolled
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
Phase 2 Completed
35 enrolled
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
77 enrolled 12 charts
DELTA
Phase 2 Completed
125 enrolled 25 charts
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase 2 Completed
16 enrolled 15 charts
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Phase 2 Completed
21 enrolled 10 charts
SHIVERING 2
Phase 2 Completed
122 enrolled 10 charts
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
14 enrolled 22 charts
CaRD
Phase 2 Completed
31 enrolled 10 charts
Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
50 enrolled
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Phase 2 Completed
94 enrolled 8 charts
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase 2 Completed
33 enrolled 8 charts